Mach7 Technologies Ltd. · ASX:M7T
Mach7 Technologies — Non-Deal Roadshow (May 2024)
13 slides from Mach7 Technologies's roadshow presentation, May 13, 2024
Slide 1: ASX Announcement: Mach7 Investor Roadshow Presentation
ASX Announcement 13 May 2024 Mach7 Investor Roadshow Presentation Mach7 Technologies Limited (“M7T” or “the Company”) (ASX:M7T), a company specialising in innovative imaging software solutions, today provides the attached presentation ahead of an investor roadshow by the CEO Mike Lampron in Sydney a
Slide 2: Investor Roadshow Presentation
Investor Roadshow Presentation For personal use only May 2024 Dr Eliot L. Siegel, leading radiologist and Issued 18 February 2021, Mach7 Non-Executive Director approved by the Board 1 1
Slide 3: Our Business
For personal use only Our Business Our Purpose To enable exceptional patient care by empowering healthcare providers to make more informed decisions. Our Offering Innovative data storage, management and image viewing solutions for the healthcare enterprise. 2
Slide 4: Our Value Proposition
Our Value Proposition Global Company with a Personal Touch Lasting Technology Built for the Entire Enterprise For personal use only A future-proof solution built on a modern A software-only solution designed for the whole technology stack that allows customers to grow, healthcare organisation. adapt
Slide 5: Our Solution – Enterprise Imaging Platform
Our Solution – Enterprise Imaging Platform Enterprise Data Management Enterprise Diagnostic Viewing Workflow Orchestration For personal use only Vendor Neutral Archive eUnity Enterprise Diagnostic Viewer Communication Workflow Engine ✓ Consolidate ALL images across the enterprise ✓ Zero footprint HT
Slide 6: Our Global Organisation
Our Global Organisation GEOGRAPHY FUNCTION For personal use only Canada 28 Executive & Admin 27 Engineering USA 34 Head count 68 108 Australia March 2024 2 Services & Singapore Sales & Support 10 Marketing 13 34 5 5
Slide 7: Our Highlights – As at March 2024
For personal use only Our Highlights – As at 31 March 2024 Record Sales Orders CARR2 ARR3 (TCV)1 A$28.2M A$22.3M run rate YTD FY24 A$56.9M +5% on A$26.8M +20% on A$18.6M Q3 FY24: A$7.4M at 31 Dec 2023 at 31 Dec 2023 New contracts, strong Strong financial position Renewed Board renewal program with n
Slide 8: Our Momentum - CARR Leading Indicator of Future Recurring Revenue
Our Momentum - CARR Leading Indicator of Future Recurring Revenue Acceleration in subscription transition to drive future ARR growth For personal use only A$M Sales Order Composition (TCV) CARR is Leading Indicator of ARR A$M 50 30 45 A$5.9M 40 25 backlog 35 20 30 25 15 20 15 10 10 5 5 - FY21 FY22 F
Slide 9: Our Strategy
Our Strategy • Provide solutions that will compete at the enterprise level in selected market segments; Our Business focused on value-based solutions Objectives For personal use only • Grow recurring revenue, stay grounded in our purpose, and protect our ability to expand into new future revenue str
Slide 10: A Transformational Year to Date
A Transformational Year to Date Positioning Mach7 for long-term growth For personal use only 1 Record sales orders of A$56.9M for the nine months to 31 March 2024 2 Successful completion of large renewal program creating foundational book of business for medium term 49% 58% 32% 3 Strong growth deliv
Slide 11: Outlook
For personal use only Outlook Fragmentation Complex Product Sales pipeline opportunities opportunities Innovation opportunities • Fragmented imaging • More complex reading • Invest in product • Following successful market with legacy environments and remote innovation to reflect a completion of larg
Slide 12: Contact Us
For personal use only Contact Us Investor Relations, Mach7 Françoise Dixon +61 (0) 412 292 977 ir@mach7t.com Registered Office: Level 4 | 100 Albert Road, South Melbourne, VIC This document was authorised for release to the ASX by Mike Lampron, Managing Director and Chief Executive Officer Issued 18
Slide 13: Disclaimer “forward looking” statements
Disclaimer “forward looking” statements Summary of information: This presentation contains general and background information about Mach7 Risks: An investment in M7T securities is subject to investment and other known and unknown risks, Technologies Limited (“M7T”) activities current as at the date